Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.05.5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends
09.05.HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
09.05.Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales
09.05.NewBiologix licenses cell line technology to Recipharm Advanced Bio
09.05.FDA chief Martin Makary sets June deadline for genAI rollout
09.05.Haya secures $65m in Series A funds to advance heart failure treatment
08.05.Viralgen and Trogenix to progress gene therapy for glioblastoma
08.05.VC firm Vivo Capital outlays $740m for biotech investment
08.05.BioVaxys and Sona partner to develop cancer therapeutics
08.05.ARS Pharma's epinephrine nasal spray 1mg now available in US
07.05.European biotechs must understand US culture while seeking funding
07.05.FDA grants RMAT status to Opus Genetics' OPGx-LCA5 gene therapy
07.05.Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
07.05.Sarepta shares fall amid FDA's CBER appointment and weak Elevidys sales
07.05.Solve FSHD to invest in Armatus Bio for ARM-201 development
07.05.Expediting parallel drug approval pathways is challenging, but rewarding
07.05.EC approves AstraZeneca's Calquence combo to treat MCL
06.05.Eli Lilly signs $415m deal for Alchemab's ALS therapy
06.05.Pharma M&A deal value surges by 101% QoQ in Q1 2025 despite US political turbulence
06.05.Recursion axes drug programmes to streamline pipeline
06.05.Veraxa and OmniAb to develop bispecific ADC tumour programme
06.05.US government exercises $144m option for smallpox/mpox vaccine contract
06.05.GLP-1 receptor agonists poised to redefine treatment paradigms beyond diabetes and obesity
06.05.Bristol Myers Squibb announces $40bn US investment plan over five years
06.05.Swiss biotech sector's R&D investment grew in 2024 despite global trends